We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
London-headquartered artificial intelligence company Kuano has raised £1m in seed funding to accelerate the development of its platform, focused on transforming the discovery of therapeutics targeting enzyme inhibition.